No Data
No Data
Longeveron Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Longeveron's Promising Alzheimer's Treatment and Favorable Regulatory Developments Drive Buy Rating
Longeveron Announces Outcome of Type B Meeting With FDA on Lomecel-B
Longeveron Says Co. And FDA Reached Foundational Alignment On Overall Study Design Supporting Laromestrocel In Alzheimer's Disease
Express News | Longeveron Inc: Company Anticipates Initiating Pivotal Clinical Trial in Second Half of 2026
Express News | Longeveron Inc - Trial Achieved Primary Safety and Secondary Efficacy Endpoints